Genialis, Inc
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
177 Huntington Ave Ste 1703, Boston, Mas...Phone Number
(617) 237-0085Website
www.genialis.comRevenue
$10.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Genialis, Inc
Genialis is a precision oncology company focused on transforming promising molecules into life-saving medicines. They utilize advanced AI models to address challenges in cancer treatment, such as patient variability in response to medications and the high failure rate of clinical trials. Their technology includes the Genialis Supermodel and multiomics data infrastructure, which provide therapeutic intelligence throughout the drug development lifecycle. Genialis aims to enhance patient stratification and improve clinical success rates in oncology.Explore more
Genialis, Inc Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Genialis, Inc your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Genialis, Inc has new funding data
Product Launch: Get notified when Genialis, Inc launches new products
Check if Genialis, Inc has recently received funding, and reach out quickly before it becomes old news!
Genialis, Inc, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Genialis, Inc is spiking on competitors!
Click to see if Genialis, Inc had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Genialis, Inc
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Genialis, Inc recently announced quarterly report
Recommended Actions
Find VP level buyers at Genialis, Inc
Find 2 more new buyers
Compare Similar Companies to Genialis, Inc
Compare insights from companies similar to Genialis, Inc, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Genialis, Inc is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Genialis, Inc is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Genialis, Inc.
Genialis, Inc financials insights
Gather financial insights about Genialis, Inc, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Angel/Seed
$2.3M
2023
Series A
$13M
Genialis, Inc Tech Stack
A closer look at the technologies used by Genialis, Inc
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Sales, Search, Software, Medical Research, Field /Outside Sales, Artificial Intelligence, Field Marketing, Healthcare Operations, Healthcare Technology, Operations
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Executive Move
Executive Moves, Board of Directors
Partnership
Partnership, Research & Development
Event
Events
Genialis, Inc News & Media
Genialis Advances Biomarker Discovery to Reduce Risk in Cancer Drug Development Targeting DNA Damage Response Pathways
BOSTON--(BUSINESS WIRE)-- #ISO27001--Genialis and Debiopharm expand collaboration to develop RNA-based predictive biomarkers for DDR therapies, advancing precision oncology.Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical care for cancer patients is hindered by insufficient biomarkers that fail to accurately predict patient response to treatment.Genialis Highlights Potential of Xerna TME Panel as a Predictive Biomarker in Poster at SITC 39th Annual Meeting
With a new partnership with India-based 4baseCare, Genialis addresses the gap in data representation to ensure its AI/ML models work in more diverse populations HOUSTON, TX, UNITED STATES, November 8, 2024 /EINPresswire.com/ -- Genialis, the RNA …Exploring Slovenia’s tech landscape
The Slovenian tech ecosystem is rapidly emerging as a hub of innovation, driven by a strong focus on research and development, a skilled workforce, and government support.Strategically located in Cent...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Genialis, Inc
Sign Up For FreeTo access detailed company insights
Genialis is a precision oncology company focused on transforming promising molecules into life-saving medicines. They utilize advanced AI models to address challenges in cancer treatment, such as patient variability in response to medications and the high failure rate of clinical trials. Their technology includes the Genialis Supermodel and multiom... Read More
